Released May 12, 2026, after the close
10-Q filed May 12, 2026, 42 days after period end · 0001390478-26-000008
Q1 2026 · 10-Q
Revenue—
Net Income-$8.41M-$8.41M N/M vs Q1 2025N/M vs Q4 2025
EPS Diluted-$0.05-$0.05 N/M vs Q1 2025no prior Q4 2025 on file
Operating Income-$9,252,000N/M
Operating Cash Flow-$8,846,000N/M
What the release said
The release
Same quarter
| Metric | Q1 2026 | Q1 2025 | Q1 2024 | Q1 2023 |
|---|---|---|---|---|
| Revenue | — | — | — | $0.00 |
| Net Income | -$8.41M | -$5.81M | -$9.57M | -$11.10M |
| EPS Diluted | -$0.05 | -$0.07 | -$0.21 | -$0.47 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
SELLAS Life Sciences Group, Inc. · CIK 1390478 · Engraved from SEC EDGAR